Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes.

Binkley E, Triozzi PL, Rybicki L, Achberger S, Aldrich W, Singh A.

Br J Ophthalmol. 2019 Aug 1. pii: bjophthalmol-2019-314461. doi: 10.1136/bjophthalmol-2019-314461. [Epub ahead of print]

PMID:
31371315
2.

Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.

Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalani NI, El-Haddad G, Triozzi PL, Moros EG, McLaughlin ML, Wadas TJ, Morse DL.

J Nucl Med. 2019 Aug;60(8):1124-1133. doi: 10.2967/jnumed.118.217240. Epub 2019 Feb 7.

PMID:
30733316
3.

Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.

Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL.

Oncol Lett. 2019 Jan;17(1):1349-1356. doi: 10.3892/ol.2018.9724. Epub 2018 Nov 19.

4.

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy.

Raj S, Miller LD, Triozzi PL.

Sarcoma. 2018 Aug 12;2018:9305294. doi: 10.1155/2018/9305294. eCollection 2018. Review.

5.

Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes.

Bhatt NB, Pandya DN, Dezarn WA, Marini FC, Zhao D, Gmeiner WH, Triozzi PL, Wadas TJ.

Methods Mol Biol. 2018;1790:197-208. doi: 10.1007/978-1-4939-7860-1_15.

6.

Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness.

Soto-Pantoja DR, Wilson AS, Clear KY, Westwood B, Triozzi PL, Cook KL.

Oncotarget. 2017 Aug 3;8(46):80545-80559. doi: 10.18632/oncotarget.19849. eCollection 2017 Oct 6.

7.

Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.

Joshi P, Kooshki M, Aldrich W, Varghai D, Zborowski M, Singh AD, Triozzi PL.

Clin Exp Metastasis. 2016 Dec;33(8):829-838. Epub 2016 Aug 26.

PMID:
27565163
8.

Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma.

Triozzi PL, Achberger S, Aldrich W, Crabb JW, Saunthararajah Y, Singh AD.

Clin Epigenetics. 2016 Jul 22;8:80. doi: 10.1186/s13148-016-0243-0. eCollection 2016.

9.

Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis.

Schuermeyer I, Maican A, Sharp R, Bena J, Triozzi PL, Singh AD.

JAMA Ophthalmol. 2016 Jan;134(1):51-6. doi: 10.1001/jamaophthalmol.2015.4343.

PMID:
26539659
10.

Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma.

Triozzi PL, Aldrich W, Crabb JW, Singh AD.

Melanoma Res. 2015 Dec;25(6):510-8. doi: 10.1097/CMR.0000000000000207.

PMID:
26397048
11.

Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications.

Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL.

Br J Ophthalmol. 2016 Apr;100(4):456-62. doi: 10.1136/bjophthalmol-2015-306921. Epub 2015 Jul 31.

PMID:
26231747
12.

Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA.

Cancer Genet. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. Epub 2014 Aug 29.

PMID:
25442074
13.

Uveal melanoma: evidence for adjuvant therapy.

Choudhary MM, Triozzi PL, Singh AD.

Int Ophthalmol Clin. 2015 Winter;55(1):45-51. doi: 10.1097/IIO.0000000000000057. Review. No abstract available.

PMID:
25436492
14.

Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Triozzi PL, Schoenfield L, Plesec T, Saunthararajah Y, Tubbs RR, Singh AD.

Oncoimmunology. 2014 Oct 31;8(10):e947169. doi: 10.4161/21624011.2014.947169. eCollection 2019.

15.

Adjuvant Therapy of Uveal Melanoma: Current Status.

Triozzi PL, Singh AD.

Ocul Oncol Pathol. 2014 Oct;1(1):54-62. doi: 10.1159/000367715. Epub 2014 Sep 10. Review.

16.

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD.

Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. doi: 10.1111/pcmr.12304. Epub 2014 Sep 1. Review.

17.

Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.

Joshi P, Jacobs B, Derakhshan A, Moore LR, Elson P, Triozzi PL, Borden E, Zborowski M.

Oncotarget. 2014 May 15;5(9):2450-61.

18.

Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.

Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL.

Mol Immunol. 2014 Apr;58(2):182-6. doi: 10.1016/j.molimm.2013.11.018. Epub 2013 Dec 25.

19.

The role of the immune response in merkel cell carcinoma.

Triozzi PL, Fernandez AP.

Cancers (Basel). 2013 Feb 28;5(1):234-54. doi: 10.3390/cancers5010234.

20.

Circulating melanoma cells: scoping the target.

Joshi P, Zborowski M, Triozzi PL.

Front Oncol. 2013 Aug 12;3:189. doi: 10.3389/fonc.2013.00189. eCollection 2013. No abstract available.

21.

Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.

Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL.

Clin Cancer Res. 2013 Jul 15;19(14):3996-4007. doi: 10.1158/1078-0432.CCR-12-2079. Epub 2013 Apr 15.

22.

The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.

Triozzi PL, Achberger S, Aldrich W, Singh AD, Grane R, Borden EC.

J Transl Med. 2012 Dec 5;10:241. doi: 10.1186/1479-5876-10-241.

23.

Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma.

Triozzi PL, Elson P, Aldrich W, Achberger S, Tubbs R, Biscotti CV, Singh AD.

Melanoma Res. 2013 Feb;23(1):1-7. doi: 10.1097/CMR.0b013e32835b7154.

PMID:
23196330
24.

Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor.

Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R.

J Immunother. 2012 Sep;35(7):587-94. doi: 10.1097/CJI.0b013e31826b20b6.

PMID:
22892455
25.

Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array.

Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C.

Invest Ophthalmol Vis Sci. 2012 Jun 5;53(7):3331-9. doi: 10.1167/iovs.11-9027.

26.

Blood biomarkers for uveal melanoma.

Triozzi PL, Singh AD.

Future Oncol. 2012 Feb;8(2):205-15. doi: 10.2217/fon.11.150. Review.

PMID:
22335584
27.

Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.

Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y.

Cancer Immunol Immunother. 2012 Sep;61(9):1441-50. doi: 10.1007/s00262-012-1204-x. Epub 2012 Feb 5.

PMID:
22310929
28.

VB-111 for cancer.

Triozzi PL, Borden EC.

Expert Opin Biol Ther. 2011 Dec;11(12):1669-76. doi: 10.1517/14712598.2011.618122. Epub 2011 Oct 1. Review.

PMID:
21961496
29.

Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.

Triozzi PL, Aldrich W, Ponnazhagan S.

Cancer Gene Ther. 2011 Dec;18(12):850-8. doi: 10.1038/cgt.2011.54. Epub 2011 Aug 26.

30.

Re-inventing intratumoral immunotherapy for melanoma.

Triozzi PL, Tuthill RJ, Borden E.

Immunotherapy. 2011 May;3(5):653-71. doi: 10.2217/imt.11.46.

PMID:
21554094
31.

Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma.

Triozzi PL, Aldrich W, Singh A.

Invest Ophthalmol Vis Sci. 2011 Jul 25;52(8):5529-35. doi: 10.1167/iovs.10-6331.

32.

Blood biomarkers of uveal melanoma metastasis.

Triozzi PL, Singh AD.

Br J Ophthalmol. 2011 Jan;95(1):3-4. doi: 10.1136/bjo.2010.193896. No abstract available.

PMID:
21163819
33.

Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.

Triozzi PL, Aldrich W, Ponnazhagan S.

Vaccine. 2010 Nov 23;28(50):7837-43. doi: 10.1016/j.vaccine.2010.09.086. Epub 2010 Oct 27.

PMID:
20937315
34.
35.

Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.

Triozzi PL, Aldrich W, Dombos C.

Melanoma Res. 2008 Dec;18(6):420-30. doi: 10.1097/CMR.0b013e3283194118.

PMID:
18971787
36.

Endoresection for choroidal melanoma: palliative or curative intent?

Singh AD, Triozzi PL.

Br J Ophthalmol. 2008 Aug;92(8):1015-6. doi: 10.1136/bjo.2008.145805. No abstract available.

PMID:
18653591
37.

Targeted therapy for uveal melanoma.

Triozzi PL, Eng C, Singh AD.

Cancer Treat Rev. 2008 May;34(3):247-58. doi: 10.1016/j.ctrv.2007.12.002. Epub 2008 Jan 28. Review.

PMID:
18226859
38.

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.

Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, Fujimori M, Conry RM.

Cancer Biother Radiopharm. 2006 Dec;21(6):561-8.

PMID:
17257071
39.

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.

Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A.

Cancer Biother Radiopharm. 2006 Dec;21(6):553-60.

PMID:
17257070
40.

Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.

Aldrich WA, Ren C, White AF, Zhou SZ, Kumar S, Jenkins CB, Shaw DR, Strong TV, Triozzi PL, Ponnazhagan S.

Gene Ther. 2006 Jan;13(1):29-39.

PMID:
16136165
41.

Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.

Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ.

Prostate. 2005 Dec 1;65(4):316-21.

PMID:
16015596
42.

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.

Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM.

J Immunother. 2005 Jul-Aug;28(4):382-8.

PMID:
16000957
43.

Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM.

Clin Cancer Res. 2005 Jun 1;11(11):4168-75.

44.

High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN.

Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT.

Cancer Biol Ther. 2005 Mar;4(3):289-94. Epub 2005 Mar 20.

PMID:
15753654
45.

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM.

Hum Gene Ther. 2005 Jan;16(1):91-100.

PMID:
15703492
46.

A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).

Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong TV.

Vaccine. 2005 Jan 26;23(10):1273-83.

PMID:
15652670
48.

Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.

Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL.

Hum Gene Ther. 2004 Sep;15(9):856-64.

PMID:
15353040
49.

Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule.

Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, Kawakami Y, Curiel DT, Blackwell JL.

Mol Ther. 2004 May;9(5):712-20.

Supplemental Content

Loading ...
Support Center